Marie Bosslett, Assistant Editor

Scott Batty, MD, and Chris VanDeusen, PhD, provided insights on AX-158's phase 2a results, presented at the SID Annual Meeting.

A pediatric patient with Peeling Skin Syndrome observed overall skin healing with no adverse events after 12 weeks of treatment.

Combining tofacitinib with UVB therapy significantly enhances vitiligo treatment outcomes, improving recovery rates and quality of life for patients.

Even with the recent rise of social media guidance, patients still trust dermatologists over social media influencers for acne treatment.

In honor of Melanoma Awareness Month, Glowbar CEO Rachel Liverman spoke to Dermatology Times about this new collaboration, which aims to increase patients' daily sunscreen use by 2026.

In a new study, AI-driven personalized treatments significantly enhanced hair growth and scalp health, offering innovative solutions for hair loss management.

In case you missed it, this week we had news about roflumilast’s dual-site efficacy in psoriasis patients, melanoma care in the United States, phase 2a safety and efficacy results of AX-158, and more.

The promising safety and efficacy results were presented at the Society for Investigative Dermatology 2025 Annual Meeting.

Social media reshapes dermatology, but misinformation about acne treatments on platforms like TikTok raises concerns among clinicians and patients alike.

New research from AAD 2025 highlights upadacitinib's effectiveness over dupilumab for treating atopic dermatitis, especially in challenging facial and neck areas.

Explore innovative strategies for managing alopecia areata with insights from expert Susan Taylor, MD, FAAD, highlighting breakthrough JAK inhibitors and real-world case studies.

Ixekizumab shows promise in restoring clinical response for hidradenitis suppurativa patients previously unresponsive to adalimumab, highlighting new treatment options.

In case you missed it, this week we had news about the first FDA-approved gene therapy for RDEB, the influence of psoriasis on sun tanning addiction, and resources for Rosacea Awareness Month.

A novel electrotrichogenic device shows promising results in promoting dense, thickened hair growth for male androgenetic alopecia patients.

Stage IV melanoma survivors face persistent adverse effects and distress, highlighting the need for targeted psychological support and care.

A study reveals that combining botulinum toxin A and hyaluronic acid significantly reduces acne-related enlarged pores, enhancing skin texture and patient satisfaction.

A new study reveals the effectiveness of two isotretinoin doses for treating recalcitrant facial flat warts, enhancing quality of life and reducing anxiety.

The developement of bempikibart offers hope for effective treatment of severe alopecia areata amid unmet medical needs.

Explore the latest insights, strategies, and treatments for patients with rosacea as Dermatology Times looks back on Rosacea Awareness Month.

Younger patients with moderate to severe psoriasis exhibit risky sun exposure behaviors, raising concerns about tanning addiction and skin cancer risks.

The innovative 21-item Hair & Scalp CARE questionnaire is designed to evaluate the psychological impact of hair and scalp conditions on quality of life.

The groundbreaking GLPSGLT serum enhances skin quality for GLP-1 RA users, improving elasticity and reducing wrinkles in just 6 weeks.

A new study reveals a significant link between acne prevalence and high BMI in Sudanese adolescents, highlighting gender differences and the need for further research.

In case you missed it, this week we had news about the future of regenerative aesthetics, biologic therapies for bullous pemphigoid, phase 3 trial results for Qtorin 3.9% rapamycin gel, and more.

Sophisticated colloidal oat emollients show promise in effectively managing pediatric atopic dermatitis, enhancing skin hydration and reducing flare-ups in infants.

A recent meta-analysis evaluates the efficacy and safety of various JAK inhibitors for alopecia areata, highlighting 12 mg twice daily deuruxolitinib as the most effective treatment.

A pilot study reveals a dual-length microneedle RF device effectively reduces neck wrinkles by 35%, enhancing skin hydration and elasticity with minimal downtime.

DLQI score reduced by 61.8% and SCORAD score reduced by 41.8% in patients after 28 days of treatment.

While products like growth factor skincare already have demonstrated benefits, this is only the beginning, according to Prithwiraj Maitra, PhD.

Prithwiraj Maitra, PhD, Vice President of Global Skincare R&D at Allergan Aesthetics, gave his thoughts on regenerative aesthetics and other recent skincare advancements.